Sex as a Biological Variable
Biological differences may contribute to variations in the safety and efficacy of medical products

On this page: Understanding sex differences at FDA | Women in clinical trials | Related links
Understanding sex differences at FDA
Research has shown that biological differences between men and women (differences due to sex chromosome or sex hormones) may contribute to variations seen in the safety and efficacy of drugs, biologics, and medical devices. FDA’s regulations and guidance acknowledge that understanding mechanisms of sex differences in medical product development is crucial for regulatory decisions and optimal treatment outcomes.
FDA’s Office of Women’s Health (OWH) advocates for the participation of women in clinical trials, supports scientific sex differences research within and outside FDA, and provides sex differences training and other resources for health professionals.
Women in clinical trials
OWH was established in 1994 to advocate for the participation of women in clinical trials and the analyses of data by sex. OWH supports studies to track the participation of women in clinical trials and collaborates with FDA's centers and external partners to conduct trainings, workshops, outreach, and research to improve clinical trials design, recruitment, and analyses and to support FDA regulatory policy and decision-making.
Information in this section is provided for historical context, and should not be considered the most current information. For current information, see Women in Clinical Trials, Women’s Health Research, News and Updates, and Education and Training from OWH.